{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:37:34Z","timestamp":1791805054256,"version":"4.3.4"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Relmacabtagene autoleucel (relma\u2010cel) demonstrated significant clinical outcomes for \u22653 lines of treatment for relapsed or refractory (R\/R) follicular lymphoma (FL) in the RELIANCE study. The primary end\u2010point was the complete response rate (CRR) at 3\u2009months. Key secondary end\u2010points included the duration of response (DOR), progression\u2010free survival (PFS), overall survival (OS) and frequency\/severity of adverse events (AEs). Relma\u2010cel\u2010treated patients (<jats:italic>N<\/jats:italic>\u2009=\u200928) had a median age of 54\u2009years (range: 36\u201371\u2009years), and more than 60% of the patients received \u22653 lines of prior systemic therapies. The median follow\u2010up was 24.4\u2009months. As previously reported, in the primary analyses set (<jats:italic>n<\/jats:italic>\u2009=\u200927), the 3\u2010month CRR was 85.2% and the 3\u2010month overall response rate was 100.0%. The median DOR, PFS and OS were not reached. As updated in this article, the estimated 2\u2010year PFS and OS rates were 80.3% and 100% respectively. During the 90\u2010day treatment\u2010emergent period (<jats:italic>N<\/jats:italic>\u2009=\u200928), no patients had cytokine release syndrome of grade \u22653, and neurological toxicity of grade \u22653 occurred in only one patient treated with 100\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> chimeric antigen receptor T cells. Neutropenia (39.3%) was the most common grade \u22653 treatment\u2010emergent adverse event. There were no AEs leading to death. Relma\u2010cel demonstrated durable remissions and manageable safety without new safety signals during the 2\u2010year follow\u2010up in patients with R\/R FL (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, NCT04089215).<\/jats:p>","DOI":"10.1111\/bjh.20122","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:50:12Z","timestamp":1756716612000},"page":"1476-1483","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Two\u2010year follow\u2010up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in <scp>RELIANCE<\/scp> study"],"prefix":"10.1111","volume":"207","author":[{"given":"Yuqin","family":"Song","sequence":"first","affiliation":[{"name":"Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-4913","authenticated-orcid":false,"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Lymphoma &amp; Myeloma Institute of Hematology &amp; Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences &amp; Peking Union of Medical College  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences  Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6617-8298","authenticated-orcid":false,"given":"Jianqiu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Jiangsu Institute of Cancer Research, Jiangsu Red Cross Cancer Center, Jiangsu Cancer Hospital, Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1813-9815","authenticated-orcid":false,"given":"Ye","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Dongfang Hospital, Tongji University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Guangdong Academy of Science, Guangdong Provincial Peoples Hospital  Guangzhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xia","sequence":"additional","affiliation":[{"name":"JW Therapeutics (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Zhang","sequence":"additional","affiliation":[{"name":"JW Therapeutics (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zisong","family":"Zhou","sequence":"additional","affiliation":[{"name":"JW Therapeutics (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26737"},{"issue":"7","key":"e_1_2_10_3_1","first-page":"537","article-title":"Chinese guidelines for diagnosis and treatment of follicular lymphoma (2020)","volume":"41","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.251"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00400"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S381493"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15149"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14698"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(22)00033\u20103"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1918"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010263"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26711"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000838"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3686"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2171994"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158024"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3196_LBA4"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014375"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406223231215701"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.20122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:10:34Z","timestamp":1760091034000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.20122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/bjh.20122"],"URL":"https:\/\/doi.org\/10.1111\/bjh.20122","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}